Last reviewed · How we verify
PROZAC WEEKLY®
At a glance
| Generic name | PROZAC WEEKLY® |
|---|---|
| Also known as | Fluoxetine Hydrochloride (generic name) |
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cellular Aging and Neurobiology of Depression Study (NA)
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (PHASE3)
- Bioequivalence Study of Fluoxetine in Healthy Adult Subjects Under Fasting Condition (PHASE1)
- Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study (NA)
- A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture (NA)
- Fluoxetine in Multiple System Atrophy Patients (PHASE2)
- Electroacupuncture Combined With Antidepressants for Post-stroke Depression (NA)
- The Study of Antidepressant Properties and Safety of Fer-01(Soline®) on the Patients With Depression
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PROZAC WEEKLY® CI brief — competitive landscape report
- PROZAC WEEKLY® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI